These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 31433752)

  • 1. Angiotensin Type 1 Receptor Blockers in Heart Failure.
    Singh KD; Karnik SS
    Curr Drug Targets; 2020; 21(2):125-131. PubMed ID: 31433752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
    Bissessor N; White H
    Vasc Health Risk Manag; 2007; 3(4):425-30. PubMed ID: 17969373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much?
    Pitt B
    Curr Heart Fail Rep; 2009 Jun; 6(2):112-6. PubMed ID: 19486595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis.
    Khan MS; Fonarow GC; Ahmed A; Greene SJ; Vaduganathan M; Khan H; Marti C; Gheorghiade M; Butler J
    Circ Heart Fail; 2017 Aug; 10(8):. PubMed ID: 28790052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure: is there a role for angiotensin II receptor blockers?
    Boucher M; Ma J
    Issues Emerg Health Technol; 2002 Sep; (38):1-4. PubMed ID: 12243202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system.
    Cohn JN
    Adv Ther; 2007; 24(6):1290-304. PubMed ID: 18165212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The place of ARBs in heart failure therapy: is aldosterone suppression the key?
    Markan U; Pasupuleti S; Pollard CM; Perez A; Aukszi B; Lymperopoulos A
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719868134. PubMed ID: 31401939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.
    Dzau V
    J Hypertens Suppl; 2005 Apr; 23(1):S9-17. PubMed ID: 15821452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure.
    Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H;
    Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The renin-angiotensin system: the role of inhibitors, blockers, and genetic polymorphisms in the treatment and prevention of heart failure.
    Hebert PR; Foody JM; Hennekens CH
    Curr Vasc Pharmacol; 2003 Mar; 1(1):33-9. PubMed ID: 15320851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
    Bomback AS; Toto R
    Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
    Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
    BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Modern History RAAS Inhibition and Beta Blockade for Heart Failure to Underscore the Non-equivalency of ACEIs and ARBs.
    Hyman DA; Siebert VR; Birnbaum GD; Alam M; Birnbaum Y
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):215-221. PubMed ID: 32219664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin receptor blockers: Focus on cardiac and renal injury.
    Arumugam S; Sreedhar R; Thandavarayan RA; Karuppagounder V; Krishnamurthy P; Suzuki K; Nakamura M; Watanabe K
    Trends Cardiovasc Med; 2016 Apr; 26(3):221-8. PubMed ID: 26169314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.